ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Daniel Cohen, MD
AbbVie
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
97 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site Reference Id/investigator# 44850
Adelaide, Australia
- Site Reference Id/investigator# 44849
Herston, Australia
- Site Reference Id/investigator# 44852
Kogarah, Australia
- Site Reference Id/investigator# 44084
Calgary, Canada
- Site Reference Id/investigator# 43905
Vancouver, Canada
- Site Reference Id/investigator# 44755
Clichy, France
- Site Reference Id/investigator# 44758
Créteil, France
- Site Reference Id/investigator# 58884
Lyon, France
- Site Reference Id/investigator# 58887
Marseille, France
- Site Reference Id/investigator# 58886
Montpellier, France
- Site Reference Id/investigator# 44754
Paris, France
- Site Reference Id/investigator# 58889
Pessac, France
- Site Reference Id/investigator# 44760
Vandœuvre-lès-Nancy, France
- Site Reference Id/investigator# 59303
Berlin, Germany
- Site Reference Id/investigator# 59304
Berlin, Germany
- Site Reference Id/investigator# 46103
Frankfurt, Germany
- Site Reference Id/investigator# 46106
Hamburg, Germany
- Site Reference Id/investigator# 46102
Hanover, Germany
- Site Reference Id/investigator# 58922
Kiel, Germany
- Site Reference Id/investigator# 46105
Würzburg, Germany
- Site Reference Id/investigator# 44847
Auckland, New Zealand
- Site Reference Id/investigator# 43672
San Juan, Puerto Rico
- Site Reference Id/investigator# 43675
San Juan, Puerto Rico
- Site Reference Id/investigator# 45363
Barcelona, Spain
- Site Reference Id/investigator# 45668
Barcelona, Spain
- Site Reference Id/investigator# 46485
Barcelona, Spain
- Site Reference Id/investigator# 45667
Madrid, Spain
- Site Reference Id/investigator# 46484
Madrid, Spain
- Site Reference Id/investigator# 45671
Majadahonda (Madrid), Spain
- Site Reference Id/investigator# 46583
Seville, Spain
- Site Reference Id/investigator# 45405
Valencia, Spain
- Site Reference Id/investigator# 57545
Dundee, United Kingdom
- Site Reference Id/investigator# 57547
London, United Kingdom
- Site Reference Id/investigator# 58811
London, United Kingdom
- Site Reference Id/investigator# 59262
London, United Kingdom
- Site Reference Id/investigator# 57882
Nottingham, United Kingdom
- Site Reference Id/investigator# 57543
Southampton, United Kingdom
- Site Reference Id/investigator# 55530
Birmingham, Alabama, United States
- Site Reference Id/investigator# 57583
Birmingham, Alabama, United States
- Site Reference Id/investigator# 55385
Dothan, Alabama, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2011
- Primary completion
- 31 Mar 2013
- Completion
- 30 Sept 2013
- Last update posted
- 22 Apr 2015
- Registered enrollment
- 580
- Registry id
- NCT01464827
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.